Synthesis and biological evaluation of a Platinum(II)-c(RGDyK) conjugate for integrin-targeted photodynamic therapy

Chatzisideri, Theodora; Thysiadis, Savvas; Katsamakas, Sotirios; Dalezis, Panagiotis; Sigala, Ioanna; Lazarides, Theodore; Nikolakaki, Eleni; Trafalis, Dimitrios T.; Gederaas, Odrun Arna; Lindgren, Mikael; Sarli, Vasiliki

doi:10.1016/j.ejmech.2017.09.058

Cited by 44 publications

(27 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another example of cyclometalated Pt(II) complex covalently linked to an RGD cyclopeptide vector was proposed by Sarli and colleagues [44] under the shape of a targeted conjugate platform for photodynamic therapy and concomitant monitoring of drug delivery. Indeed, apart from the considerable interest raised as anticancer agents, Pt‐based complexes display interesting luminescence properties per se , which may be exploited in bioimaging and/or theranostic applications.…”

Section: Dual Conjugates Embedding Noncleavable Linkersmentioning

confidence: 99%

RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances

et al. 2021

View full text Add to dashboard Cite

In recent years, targeted therapies have raised increasing interest as effective strategies to improve therapeutic efficiency, reduce the impact of adverse side effects, and overcome drug resistance, particularly in the field of cancer chemotherapeutics. Many examples of RGD (Arg‐Gly‐Asp) peptide‐drug conjugates (PDCs) have been proposed as targeted drug delivery systems. These molecular hybrids embody high affinity ligands targeting disease signatures (overexpressed integrin receptors or specific integrin‐related pathways within diseased cells/tissues) connected to recognized therapeutic units by means of carefully designed linker‐spacer combinations, to ultimately control stability, physico‐chemical properties, timing, and localization of drug release. This account has collected and critically surveyed relevant contributions from the period of 2015 to the present day, wishing to provide a window open on new synthesis strategies facing the challenging issues of site‐selective drug delivery and dual drug targeting.

show abstract

Section: Dual Conjugates Embedding Noncleavable Linkersmentioning

confidence: 99%

RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Skin color changes to the hands and feet occurring as a result of targeted drug administration (such as sorafenib and sunitinib), referred to as the hand‐foot skin reaction (HFSR), also occur after the administration of chemotherapy drugs (such as capecitabine, fluorouracil, and doxorubicin), known as the “hand‐foot syndrome” (HFS) . HFSR and HFS may occur in the palms and soles of the feet, accompanied by tenderness, and alleviation of symptoms occurs after drug withdrawal . HFSR manifests mainly as excessive keratinization around the erythema, while HFS shows symmetrical sensory abnormalities, erythema, and edema.…”

Section: Discussionmentioning

confidence: 99%

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors

Xing

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThis study was conducted to assess the adverse reactions caused by multi‐target tyrosine kinase inhibitor treatment of gastrointestinal tumors.MethodsWe carried out a retrospective study of drug‐related adverse reactions in 115 patients who were treated with sorafenib, sunitinib, and imatinib for primary hepatocellular carcinoma or gastrointestinal stromal tumors from October 2003 to March 2012 at the Peking University International Hospital.ResultsThe total incidence of adverse reactions of sorafenib, sunitinib, and imatinib in patients with hepatocellular carcinoma and gastrointestinal stromal tumors was > 80%. The main adverse reactions of sorafenib were hypertension in 38 patients (33.3%) and diarrhea in 28 patients (24.4%). Sunitinib was associated with higher incidence and greater grade 3–4 toxicity. The common toxicities were skin color changes in 105 patients (90.9%), hand‐foot skin reactions in 65 patients (54.6%), and leukopenia (63.6%), hypertension (22.7%), proteinuria (22.7%), liver function impairment (22.7%), and hypomagnesemia (27.3%). While imatinib was well tolerated, it was associated with the highest number of adverse reactions, including skin color change (55.6%) and edema (38.9%). Hypophosphatemia (4.4%) and hoarseness (2.2%) only occurred in the sorafenib treatment group.ConclusionsThe adverse reactions of multi‐target tyrosine kinase inhibitor treatments are generally mild to moderate, and most patients can tolerate these without the need for further intervention. Some serious adverse reactions may be alleviated by discontinuing the drugs or by administering symptomatic treatment.

show abstract

“…The synthesis and biological profile of a Pt II -c(RGDyK) conjugate 25 ( Figure 10) for integrin-targeted PDT has been reported. Complex 25 was moderately cytotoxic towards six cancer cell lines with different levels of integrin expression [88]. It was taken up rapidly by receptor-mediated endocytosis and generated 1 O 2 efficiently upon irradiation, thus showing enhanced anticancer activity as a targeted PDT agent.…”

Section: Targeted Monofunctional Pt II Complexesmentioning

confidence: 99%

Monofunctional Platinum(II) Anticancer Agents

Jin

Guo

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl]+ (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.

show abstract

Synthesis and biological evaluation of a Platinum(II)-c(RGDyK) conjugate for integrin-targeted photodynamic therapy

Cited by 44 publications

References 58 publications

RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances

RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors

Monofunctional Platinum(II) Anticancer Agents

Contact Info

Product

Resources

About